NGR018: Randomized Phase II Study of NGR-hTNF Plus an Anthracycline Versus an Anthracycline Alone in Platinum-resistant Ovarian Cancer
Latest Information Update: 05 Nov 2020
At a glance
- Drugs NGR-TNF (Primary) ; Doxorubicin; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms NGR018
- Sponsors AGC Biologics; MolMed
- 02 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials database.
- 12 Aug 2013 New trial record